Skip to main content
James Pennington, MD, Infectious Disease, Lafayette, CA

James Earl Pennington MD

Infectious Disease•Lafayette, CA

Physician

Join to View Full Profile

  • 4 Toledo DrLafayette, CA 94549

  • Phone+1 925-899-5922

  • Fax+1 925-283-7876

Are you Dr. Pennington?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
Claim this profileNot you? Find your profile

Summary

  • Dr. James Pennington, MD is an infectious disease specialist in Lafayette, California. He is currently licensed to practice medicine in California.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1974 - 1975
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1970 - 1971
  • Oregon Health and Science University School of Medicine
    Oregon Health and Science University School of MedicineClass of 1969

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Press Mentions

  • AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
    AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisAugust 13th, 2020
  • AzurRx BioPharma Announces Positive Interim Data from First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
    AzurRx BioPharma Announces Positive Interim Data from First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyAugust 11th, 2020
  • AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
    AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites ActivatedJuly 22nd, 2020
  • Join now to see all

Dr. James Pennington, Dr. James Pennington, MD, Dr. J Pennington, Dr. James Earl Pennington